# ADD Indian Hotels

# Robust outlook; new hotel brand in the offing

Hotels > Result Update > February 2, 2024

Indian Hotels Company (IHCL) delivered a beat on consolidated revenue and margin, aided by standalone occupancy of 76.8% (vs. 72.1% in Q3FY23) and ARR/RevPAR growth of 17% YoY/25% YoY. IHCL expects growth to remain in double digits for FY25, with 'business on books' staying strong and new businesses expected to grow at over 30%YoY. We like IHCL's diversified topline, operational efficiency, and debt-free balance sheet. IHCL has a pipeline of 82 hotels, and is set to add ~11k rooms (~8.7k room-adds over FY24-26E). This will aid consol. revenue/EBITDA CAGR of 14%/19% over FY23-26E, amid margin expansion. We raise FY25E/FY26E EBITDA by 7%/6%, on the results beat. We maintain ADD on IHCL, with TP of Rs525/sh (Rs485 earlier), ascribing 24x Dec-25E EV/EBITDA (23.5x earlier) amid continued strength in business.

Indian Hotels: Financial Snapshot (Consolidated)									
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E				
Revenue	30,562	58,099	67,797	77,384	86,194				
EBITDA	4,048	18,046	21,970	26,573	30,072				
Adj. PAT	(2,805)	10,495	13,686	17,947	21,566				
Adj. EPS (Rs)	(2.0)	7.4	9.6	12.6	15.2				
EBITDA margin (%)	13.2	31.1	32.4	34.3	34.9				
EBITDA growth (%)	0.0	345.8	21.7	20.9	13.2				
Adj. EPS growth (%)	0.0	0.0	30.4	31.1	20.2				
RoE (%)	(5.2)	14.0	15.8	17.6	17.8				
RoIC (%)	0.0	12.3	14.4	18.0	20.4				
P/E (x)	(250.6)	67.0	51.4	39.2	32.6				
EV/EBITDA (x)	172.9	38.3	30.9	25.0	21.4				
P/B (x)	10.0	8.8	7.5	6.3	5.3				
FCFF yield (%)	(0.1)	1.2	2.2	2.8	3.5				

Source: Company, Emkay Research

### Beat on Q3 estimates; standalone RevPAR up 25% YoY

Consol. revenue stood at 16.5%, up YoY (3%/6% above Street/our expectations). Company has maintained the growth momentum seen in Q1/Q2 (16%YoY each). EBITDA margin expanded by 190bps YoY (+1,250bps QoQ) to 37.3%, led by decline in employee cost and cost of raw material as share of revenue. Standalone revenue was up 20.6% YoY to Rs12.8bn (9% above our estimate) vs. 17%YoY/19%YoY growth in Q1/Q2, indicating pickup in momentum. Standalone occupancy was 76.8%, up by 470bps YoY. ARR was at 17% YoY, leading to RevPAR improving 25% YoY. Implied subsidiary revenue was up 9% YoY vs. 12%YoY/14% YoY growth in Q2/Q1, pointing to moderation in growth rate. New Business clocked growth of 33% YoY, with TajSATS clocking 34% YoY growth.

#### Growth to sustain in double digits as new businesses grow at a fast pace

IHCL expects revenue growth to sustain in double-digits YoY, aided by i) continued addition keys with an over 11.1k strong pipeline for FY24-27 (~8.5k through management contract); ii) new businesses growing at over 30% YoY aided by Qmin being added to more Ginger hotels, Ama Stays & Trails revenue doubling in FY25, and TajSATS well-poised to exceed Rs10bn in revenue in FY25 (vs. Rs 6.5bn in 9MFY24). TajSATS has levers for growth with increase in number of airports/flights and rise in non-aviation revenue for TajSATS. Plans to add 2 new full-service brands at a price-point below Rs10k for tier 2/tier 3 cities can aid further growth for IHCL.

### FY23-26E EBITDA CAGR to clock at 19%; ADD

Company continues to focus on diversification of topline with new brands, along with investment in digitization that can help in mid- & long-term revenue growth and improvement in margin. Robust demand will aid RevPAR CAGR of 11% and consol. revenue/EBITDA CAGR of 14%/19% over FY23-26E, amid margin expansion. We have increased consol. EBITDA by 5%/7%/6% for FY24E/FY25E/FY26E, as we adjust for the revenue/margin beat. We maintain ADD on IHCL, with TP of Rs525/sh (Rs485 earlier), ascribing 24x Dec-25E EV/EBITDA (23.5x earlier) given continued strength in business.



### **TARGET PRICE (Rs): 525**

Target Price – 12M	Dec-24
Change in TP (%)	8.2
Current Reco.	ADD
Previous Reco.	ADD
Upside/(Downside) (%)	6.1
CMP (01-Feb-24) (Rs)	495.0
Stock Data	Ticker
52-week High (Rs)	502
52-week Low (Rs)	298
Shares outstanding (mn)	1,423.4
Market-cap (Rs bn)	705
Market-cap (USD mn)	8,491
Net-debt, FY12E (Rs mn)	0
ADTV-3M (mn shares)	3
ADTV-3M (Rs mn)	1,223.4
ADTV-3M (USD mn)	14.7
Free float (%)	-
Nifty-50	21,697
INR/USD	83.0
Shareholding, Dec-23	
Promoters (%)	38.1
FPIs/MFs (%)	23.3/22.3

Price Performance								
(%) 1M 3M 12M								
Absolute	13.5	27.2	51.5					
Rel. to Nifty	13.7	11.3	23.0					



#### Santosh Sinha

santosh.sinha@emkayglobal.com +91 22 6624 2414

*Kevin Shah kevin.shah@emkayglobal.com* +91 22 6612 1340

# Key takeaways from the earnings call

- Demand to stay robust: The healthy demand in Q3 is seen continuing in Q4FY24 (January stood strong). With increase in the booking window, Company is able to attain higher visibility till March which suggests continuation of demand momentum. This will be further accelerated by the commencement of IPL at end-March.
- ARRs to sustain: The management believes that ARR has seen negligible growth for the past several years. ARR in India is also well below that in the Asia-Pacific region (as per an STR report), with an enduring healthy demand-trend indicating further scope for ARR increase. Additionally, Bharat Mandapam, Delhi Yashobhoomi in Delhi, and addition of Jio coupled with effective asset management (including premium offering) will help the company charge higher.
- Cost optimization: As a % of revenue, cost will appear to be most efficient in Q3FY24, which is typically the strongest quarter. On an annual basis, costs at all levels have been optimized. Additionally, Company is investing towards digitization of new businesses as a part of its cost-reduction initiative.
- Healthy traction in new businesses: IHCL's new/re-imagined businesses grew 34% YoY in 9MFY24 (vs. 17% growth for the traditional business). Revenue share of new business increased to 17% from 10% in FY20, while EBITDA share increased to 24% from 16% over the same period. The company expects this growth momentum to increase, thus helping it achieve 30% growth going forward with EBITDA margin of ~35%.
  - **Ginger's** lean luxe transformation for two-thirds of its portfolio is helping it witness a healthy growth momentum and is expected to record Rs6bn revenue in FY25.
  - Ama Stays & Trails to reach portfolio-strength of 150 bungalows (100 operational) by the end of FY24. Its revenues are expected to double in FY25.
  - Qmin to achieve record Rs1bn of GMV in FY24 aided by its expansion to 34 Ginger hotels till date.
  - **TajSATS** continues to record industry-leading metrics and is well-poised to exceed Rs10bn in FY25. This will be aided by strong addition of airports and aircraft.
- International business: The international portfolio is performing well and is profitable overall, led by the UK. USA (especially New York), however, is yet to recover completely post the pandemic period. San Francisco is temporarily impacted and is now showing signs of recovery (the management expects recovery in 12-18 months).
- Hotels pipeline: IHCL opened 16 hotels in 9MFY24 and plans to open 4 more in Q4FY24. It has plans to open 2 hotels in Ayodhya one in the next 12 months and another in the next 20. The company has a total pipeline of 85 hotels, indicating an increase in the pace of hotel openings. The management plans to maintain an average of 2 hotel openings per month for the next 3 years, aided by its asset-light model.
- Ginger Mumbai (airport) debuts on a positive note: Opened (260 of the 371 rooms that are operational) with an average occupancy of 80% at an ARR of Rs6,500 (expected to move up to Rs7,500) which helped it achieve a positive PBT from the first month of operations; the management believes it will maintain this rate going ahead too. The complete official launch is scheduled for 8<sup>th</sup> February 2024.
- Two new brand launches in the pipeline for Tier 2/3 cities: IHCL targets launching new or reimagined existing brands in the coming few months. Unlike Ginger, these will be full-service brands (including banqueting, weddings, etc), with key focus on Tier 2 and Tier 3 cities. The company intends to add a minimum of 50 hotels within a single brand that gets launched. The price-points will be of Rs8,000-Rs9,000, i.e. between that of TAJ and Ginger, and similar to Vivanta's. With these brand launches, the company aims to strengthen its asset-light initiatives, support margin expansion, and make it less volatile to the market cyclicality.
- Outlook: The macro tailwinds are expected to remain strong, and so aid demand momentum with no significant uptick in supply in all key markets. Additionally, 58% of IHCL's customers are transient (non-negotiated), helping achieve high ARR. As a result, Company expects the strong growth in RevPAR (45% revenue contribution) to continue. Company believes it will register double-digit revenue growth for FY25 as well, driven by growth in its core business, new businesses, and its traditional business enabled by effective

asset management (76% of portfolio being asset-light). It expects to double its management fee from pre-Covid levels to ~Rs4.5bn in FY24.

### Other highlights:

- The upgrade of 24 Vivanta hotels to the TAJ brand is paying off positively.
- Tata Neu loyalty platform delivers with 24% of enterprise revenue coming from loyalty members. The total loyalty base stands at 5.1mn members as on date vs. 2.2mn at the time of the Tata Neu launch.
- Company has planned for capex of Rs6bn in FY24 and of Rs7.5-8bn in FY25.
- Healthy gross cash of Rs18bn gives benefit of capturing accretive opportunities.
- IHCL invested in 4 villas in Goa to strengthen its Ama brand.
- Company is on track to deliver its 2030 ESG targets with the help of Paathya, its ESG plus initiative.

# Q3FY24 results: Beat on revenue and margin

- Consol. revenue was Rs19.6bn (6% above our and 3% above street expectations), coming 16.5% up YoY. Company has maintained the growth momentum seen in Q1/Q2 (16%YoY each).
- EBITDA margin expanded by 190bps YoY (+1,250bps QoQ) to 37.3% (120bps above consensus and 150bps above our estimates). Margin expansion was led by i) 130bps decline in employee cost (as share of revenue); and ii) 50bps decline in cost of raw material (as share of revenue). Company's focus on optimizing cost and revenue flow-through has helped expand margin.
- Finance cost was down 6% YoY (-10% QoQ) at Rs0.53bn, while depreciation increased 10.6% YoY (+2.8% QoQ) to Rs1.1bn.
- EBITDA increase of 22.6%YoY aided an increase in PAT by 18% YoY to Rs4.8bn (9%/8% above consensus/our estimate).

### Standalone: Beat on revenue and margin; momentum picks up in Q3

- Standalone revenue was up 20.6% YoY to Rs12.8bn (9% above our estimate). Standalone revenue was up 17%YoY/19% YoY in Q1/Q2, indicating pickup in momentum.
- EBITDA margin expanded by 223bps YoY (1,293bps QoQ) to 43.6% (Emkay: 41.2%; at a 240bps beat).

### Subsidiary: Growth rate moderating

- Implied subsidiary revenue was up 9% YoY to Rs6.8bn (in line with our estimate). Growth rate YoY has been moderating, with growth of 12%/14% in Q2/Q1.
- EBITDA margin expanded by 15bps YoY (1,050bps QoQ) to 25.5% (Emkay: 26.5%; at a 100bps miss).

### **KPIs and other highlights**

- Standalone occupancy was 76.8% (vs. 72.1% in Q3FY23 and 75.9% in Q2FY24), up 470bps YoY. Bengaluru (+4ppts YoY) and Goa (+5ppts YoY) registered good improvement in occupancy YoY.
- ARR of Rs18,111, up 17% YoY (vs. +18% YoY/11% in Q2/Q1FY24).
- RevPAR was up 25% YoY at Rs13,918 vs. 28% YoY/18% YoY growth in Q2/Q1 (a 12% beat). In Q3, Mumbai, Rajasthan, Hyderabad and Kolkata logged RevPAR growth of over 20% YoY in Q3. Internationally, Sri Lanka (+95% YoY); Cape Town (+37%); Dubai/UK (+10%) registered good growth in RevPAR; Maldives (-9%) and USA (-3%) registered degrowth in RevPAR.
- UOH INC (USA) registered de-growth in revenue/EBITDA.
- Chambers: Over 50 Chamber members were added in Q3, taking the total to over 2,850.
  Q3 revenue was Rs300mn from Chambers vs. Rs540mn in H1.

- TajSATS: Company's air catering business, TajSATS, clocked revenue of Rs2.33bn, 34% YoY growth (vs. 48% YoY/55% YoY growth in Q2/Q1). Margin improved, from 24.4% in Q2 to 26% in Q3.
- New Business clocked growth of 33% YoY (11.1% of revenue in Q3FY24 vs. 9.8% last year), while IHCL Enterprise revenue was up 17% YoY.
- Management Fee income grew 13% YoY vs. 14% YoY in Q2, indicating continued focus on its asset-light strategy.
- IHCL signed 11 hotels in Q3 (vs. 6/11 in Q2/Q1).
- IHCL opened 8 new hotels in Q3 (vs. 3/5 new hotels in Q2/Q1).
- IHCL's recent signings include destinations like Ayodhya, Itanagar, Dibrugarh, Surat, Dehradun, and Chitwan in Nepal.

### **Exhibit 1: Consolidated results**

Consolidated P&L (Rs mn)	Q3FY23	Q2FY24	Q3FY24	Chg YoY %	Chg QoQ %
Revenue	16,858	14,332	19,638	16.5	37.0
Costs of RM	1,405	1,124	1,532	9.1	36.4
Employee costs	4,244	4,405	4,686	10.4	6.4
Fuel, Power & Light	740	810	730	(1.4)	(9.9)
Other Expenses	4,497	4,445	5,366	19.3	20.7
Total Expenses	10,886	10,784	12,315	13.1	14.2
EBITDA	5,972	3,548	7,324	22.6	106.4
D&A	1,033	1,112	1,143	10.6	2.8
EBIT	4,939	2,436	6,181	25.1	153.8
Other Income	577	477	398	(31.0)	(16.5)
Finance Costs	567	591	532	(6.3)	(10.0)
PBT before Xo	4,949	2,322	6,047	22.2	160.4
Exceptional gain/(loss)	1	-	-		
PBT after Xo	4,950	2,322	6,047	22.2	160.4
Tax	1,161	723	1,667	43.6	130.7
Profit/(loss) of JV/Associate	246	191	389	58.0	104.3
РАТ	4,036	1,790	4,769	18.2	166.5
АРАТ	4,035	1,790	4,769	18.2	166.5
% of Revenue	Q3FY23	Q2FY24	Q3FY24	Chg YoY (bps)	Chg QoQ (bps)
Revenue	100.0	100.0	100.0	-	-
Cost of RM	8.3	7.8	7.8	(53)	(4)
Employee costs	25.2	30.7	23.9	(131)	(687)
Fuel, Power & Light	4.4	5.7	3.7	(67)	(193)
Admin & Other Expenses	26.7	31.0	27.3	65	(369)
Total Expenses	64.6	75.2	62.7	(187)	(1,254)
EBITDA	35.4	24.8	37.3	187	1,254
D&A	6.1	7.8	5.8	(31)	(194)
EBIT	29.3	17.0	31.5	217	1,448

Source: Company

This report is intended for team emkay@whitemarquesolutions com use and downloaded at 05/01/2024 09:20 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

### Exhibit 2: Standalone financial result

Standalone P&L (Rs mn)	Q3FY23	Q2FY24	Q3FY24	Chg YoY %	Chg QoQ %
Revenue	10,616	8,929	12,806	20.6	43.4
Cost of RM	907	708	984	8.5	39.0
Employee costs	1,992	2,140	2,224	11.6	3.9
Fuel, Power & Light	450	500	450	-	(10.0)
Admin & Other Expenses	2,875	2,843	3,565	24.0	25.4
Total Expenses	6,224	6,191	7,223	16.0	16.7
EBITDA	4,391	2,738	5,584	27.1	103.9
D&A	519	552	586	13.0	6.1
EBIT	3,873	2,186	4,998	29.1	128.6
Other Income	218	559	426	95.6	(23.9)
Finance Costs	325	314	277	(14.7)	(11.6)
PBT before Xo	3,765	2,431	5,146	36.7	111.7
Exceptional gain/(loss)	-	(312)	-		-
PBT after Xo	3,765	2,119	5,146	36.7	142.8
Tax	934	547	1,342	43.7	145.2
РАТ	2,832	1,572	3,804	34.3	142.0
АРАТ	2,832	1,884	3,804	34.3	101.9
% of Revenue	Q3FY23	Q2FY24	Q3FY24	Chg YoY (bps)	Chg QoQ (bps)
Revenue	100.0	100.0	100.0	-	-
Costs of RM	8.5	7.9	7.7	(86)	(24)
Employee costs	18.8	24.0	17.4	(140)	(661)
Fuel, Power & Light	4.2	5.6	3.5	(73)	(209)
Admin & Other Expenses	27.1	31.8	27.8	75	(400)
Total Expenses	58.6	69.3	56.4	(223)	(1,293)
EBITDA	41.4	30.7	43.6	223	1,293
D&A	4.9	6.2	4.6	(31)	(161)
EBIT	36.5	24.5	39.0	254	1,454

Source: Company

# Exhibit 3: Standalone operational performance

	Q3FY23	Q2FY24	Q3FY24	Chg YoY %	Chg QoQ %
Occupancy (%)	72.1	75.9	76.8	470 bps	90 bps
ARR (Rs)	15,456	12,972	18,111	17.2	39.6
RevPAR (Rs)	11,144	9,840	13,918	24.9	41.4
<u>Revenue Break-up (Rs mn)</u>					
Room Revenue	4,520	4,000	5,750	27.2	43.8
F&B Revenue	4,000	3,150	4,570	14.3	45.1
Other Revenues	2,096	1,779	2,486	18.6	39.7
Total	10,616	8,929	12,806	20.6	43.4

Source: Company

This report is intended for team emkay@whitemarquesolutions com use and downloaded at 05/01/2024 09:20 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

(Rs mn)	Q3FY23	Q2FY24	Q3FY24	Chg YoY %	Chg QoQ %
Revenue	6,242	5,403	6,832	9.4	26.5
Costs of RM	498	416	548	10.1	31.8
Employee costs	2,253	2,265	2,463	9.3	8.7
Fuel, Power & Light	290	310	280	(3.4)	(9.7)
Admin & Other Expenses	1,621	1,603	1,801	11.1	12.4
Total Expenses	4,662	4,593	5,092	9.2	10.9
EBITDA	1,581	810	1,740	10.1	115.0
D&A	514	560	557	8.3	(0.5)
EBIT	1,067	250	1,183	10.9	373.5
Other Income	360	(82)	(28)	(107.6)	(66.5)
Finance Costs	243	277	255	4.9	(8.1)
PBT before Xo	1,184	(109)	901	(23.9)	(926.0)
Exceptional gain/(loss)	1	312	-	(100.0)	-
PBT after Xo	1,185	203	901	(23.9)	345.0
Tax	227	176	326	43.3	85.4
Profit/(loss) of JVs/Assoc.	246	191	389	58.0	104.3
РАТ	1,204	218	965	(19.8)	343.7
АРАТ	1,203	(94)	965	(19.8)	
% of Revenue	Q3FY23	Q2FY24	Q3FY24	Chg YoY (bps)	Chg QoQ (bps)
Revenue	100.0	100.0	100.0	-	-
Costs of RM	8.0	7.7	8.0	5	33
Employee costs	36.1	41.9	36.0	(4)	(588)
Fuel, Power & Light	4.6	5.7	4.1	(55)	(164)
Admin & Other Expenses	26.0	29.7	26.4	39	(330)
Total Expenses	74.7	85.0	74.5	(15)	(1,049)
EBITDA	25.3	15.0	25.5	15	1,049
D&A	8.2	10.4	8.2	(8)	(221)
EBIT	17.1	4.6	17.3	23	1,269

Source: Company

# Changes in estimates

### Exhibit 5: Changes in estimate

Rs		FY24E	FY25E				FY26E			
	Old	New	% Chg	Old	New	% Chg	Old	New	% Chg	
Revenue (Rs mn)	66,229	67,797	2.4	75,186	77,384	2.9	84,496	86,194	2.0	
EBITDA (Rs mn)	21,021	21,970	4.5	24,862	26,573	6.9	28,462	30,072	5.7	
EBITDA Margin (%)	31.7	32.4	67 bps	33.1	34.3	127 bps	33.7	34.9	120 bps	
APAT (Rs mn)	11,833	12,336	4.2	14,889	16,260	9.2	18,250	19,542	7.1	
AEPS (Rs mn)	9.2	9.6	4.2	11.7	12.6	7.7	14.6	15.2	4.3	

Source: Company, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 05/01/2024 09:20 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# Valuation

The de Maria	<b>c</b> .	Valuation
EXNIDIC	0:	Valuation

Valuation snapshot (Consolidated)	Dec-25E
EBITDA (Rs mn)	29,197
Target multiple (x)	24
Enterprise Value (Rs mn)	7,00,734
Less: Minority Interest (Rs mn)	7,550
Less: Net Debt (Rs mn)	(29,323)
Equity Value (Rs mn)	7,22,502
O/s shares (mn)	1,420
Value per share (Rs)	510
Add: Value of IHCL stake in TajGVK/Oriental	9
Add: Others (Rs)	6
Value per share (Rs)	525

Source: Company, Emkay Research

		FY25	FY26
Base Revpar	Rs	12,810	13,544
New Revpar	Rs	12,169	12,867
Change	%	-5.0%	-5.0%
Base Revenue	Rs mn	77,384	86,194
New Revenue	Rs mn	73,743	82,131
Change	%	-4.7%	-4.7%
Base EBITDA	Domo	26 572	20.072
	Rs mn	26,573	30,072
New EBITDA	Rs mn	23,215	26,325
Change	%	-12.6%	-12.5%
Base PAT	Rs mn	17,947	21,566
New PAT	Rs mn	15,512	18,783
Change	%	-13.6%	-12.9%
Base RoE	%	17.6%	17.8%
	%		
New RoE		15.4%	16.0%
Change	bps	-221	-180
Base RoCE	%	19.8%	19.4%
New RoCE	%	16.9%	17.0%
Change	bps	-286	-240
Base Net Debt	Rs bn	-38.2	-59.0
New Net Debt	Rs bn	-35.8	-53.9
Change	%	-6.2%	-8.7%
Base Net Debt/EBITDA	X	-1.4	-2.0
New Net Debt/EBITDA	X	-1.5	-2.0
Change	%	7.3%	4.3%
Base TP	Rs	525	
New TP	Rs	460	
Change	%	-12.4%	

## Exhibit 7: Sensitivity for 5% decline in RevPAR

Source: Emkay Research, Company


This report is intended for team emkay@whitemarquesolutions.com use and downloaded at 05/01/2024 09:20 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# Exhibit 8: IHCL has a pipeline of 11k rooms

	Curre	Current		ine	Tota	al
Brands	No. of Hotels	No. of Rooms	No. of Hotels	No. of Rooms	No. of Hotels	No. of Rooms
Тај	84	12,233	21	3,833	105	16,066
Vivanta	29	3,992	23	3,142	52	7,134
SeleQtions	23	1,567	13	1,250	36	2,817
Ginger	62	5,376	25	2,889	87	8,265
Total	198	23,168	82	11,114	280	34,282


Source: Company

### Exhibit 9: Pipeline of 82 hotels




Source: Company, Emkay Research






Source: Company, Emkay Research

# Exhibit 12: Company to clock ARR CAGR of 9% over FY23-26E...




Source: Company, Emkay Research

Exhibit 11: Share of managed rooms to be ~50% by FY26E




Source: Company, Emkay Research

### Exhibit 13: ...and RevPAR CAGR of 11% over FY23-26E




Source: Company, Emkay Research

This report is intended for team.emkay@whitemarguesolutions.com use and downloaded at 05/01/2024 09:20 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.




Source: Company, Emkay Research

### Exhibit 16: IHCL to register PAT at Rs21.6bn by FY26E...




Source: Company, Emkay Research




Source: Company, Emkay Research

Exhibit 15: ...and EBITDA CAGR of 19% over FY23-26E




Source: Company, Emkay Research

### Exhibit 17: ...RoE at 18% by FY26E




Source: Company, Emkay Research



Source: Company, Emkay Research

This report is intended for team.emkay@whitemarguesolutions.com use and downloaded at 05/01/2024 09:20 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# Exhibit 20: 1-year forward P/E



Source: Bloomberg





Source: Bloomberg

This report is intended for team emkay @whitemarguesolutions com use and downloaded at 05/01/2024 09:20 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# **Indian Hotels: Consolidated Financials and Valuations**

Profit & Loss					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Revenue	30,562	58,099	67,797	77,384	86,194
Revenue growth (%)	94.0	90.1	16.7	14.1	11.4
EBITDA	4,048	18,046	21,970	26,573	30,072
EBITDA growth (%)	0.0	345.8	21.7	20.9	13.2
Depreciation & Amortization	4,061	4,161	4,484	4,706	4,910
EBIT	(13)	13,885	17,486	21,866	25,162
EBIT growth (%)	0.0	0.0	25.9	25.1	15.1
Other operating income	0	0	0	0	0
Other income	1,552	1,389	1,725	1,953	2,698
Financial expense	4,277	2,361	2,190	1,762	1,282
PBT	(2,738)	12,914	17,021	22,058	26,578
Extraordinary items	0	0	0	0	0
Taxes	(358)	3,232	4,685	5,798	7,037
Minority interest	0	0	0	0	0
Income from JV/Associates	(426)	814	1,350	1,687	2,025
Reported PAT	(2,649)	10,529	13,686	17,947	21,566
PAT growth (%)	0.0	0.0	30.0	31.1	20.2
Adjusted PAT	(2,805)	10,495	13,686	17,947	21,566
Diluted EPS (Rs)	(2.0)	7.4	9.6	12.6	15.2
Diluted EPS growth (%)	0.0	0.0	30.4	31.1	20.2
DPS (Rs)	0.0	0.0	0.0	0.0	0.0
Dividend payout (%)	0.0	0.0	0.0	0.0	0.0
EBITDA margin (%)	13.2	31.1	32.4	34.3	34.9
EBIT margin (%)	0.0	23.9	25.8	28.3	29.2
Effective tax rate (%)	13.1	25.0	27.5	26.3	26.5
NOPLAT (pre-IndAS)	(11)	10,410	12,673	16,119	18,500
Shares outstanding (mn)	1,420.4	1,420.4	1,420.4	1,420.4	1,420.4

Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	1,420	1,420	1,420	1,420	1,420
Reserves & Surplus	69,202	78,399	91,811	109,399	130,534
Net worth	70,623	79,820	93,231	110,820	131,954
Minority interests	5,930	6,601	6,931	7,277	7,641
Deferred tax liability (net)	(704)	(15)	27	53	62
Total debt	40,226	32,829	30,687	29,655	29,211
Total liabilities & equity	116,074	119,234	130,877	147,805	168,869
Net tangible fixed assets	641	850	1,059	0	0
Net intangible assets	4	7	9	91,833	92,314
Net ROU assets	(301)	(315)	(539)	19,548	19,939
Capital WIP	1,933	3,242	2,275	2,483	2,667
Goodwill	6,229	6,536	6,536	6,536	6,536
Investments [JV/Associates]	14,502	14,084	14,789	15,528	16,304
Cash & equivalents	17,044	15,360	24,822	39,303	58,928
Current assets (ex-cash)	11,681	14,155	15,292	16,662	18,194
Current Liab. & Prov.	13,242	15,871	16,457	18,004	19,538
NWC (ex-cash)	(1,561)	(1,716)	(1,165)	(1,342)	(1,344)
Total assets	116,074	119,234	130,877	147,805	168,869
Net debt	(3,165)	(12,051)	(23,167)	(38,475)	(58,515)
Capital employed	89,728	89,716	101,844	118,978	140,071
Invested capital	82,595	86,548	88,991	90,491	90,970
BVPS (Rs)	49.7	56.2	65.6	78.0	92.9
Net Debt/Equity (x)	0.0	(0.2)	(0.2)	(0.3)	(0.4)
Net Debt/EBITDA (x)	(0.8)	(0.7)	(1.1)	(1.4)	(1.9)
Interest coverage (x)	2.8	0.2	0.1	0.1	0.0
RoCE (%)	0.0	15.5	18.3	19.8	19.4

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
PBT	(2,738)	12,914	17,021	22,058	26,578
Others (non-cash items)	8,181	6,488	6,674	6,468	6,192
Taxes paid	358	(3,232)	(4,685)	(5,798)	(7,037)
Change in NWC	(1,744)	672	(46)	772	697
Operating cash flow	3,631	17,655	20,314	25,188	28,456
Capital expenditure	(4,122)	(9,578)	(5,409)	(6,592)	(5,574)
Acquisition of business	36,539	314	1,849	2,564	3,085
Interest & dividend income	(4,871)	(3,781)	(4,928)	(5,353)	(5,596)
Investing cash flow	32,573	(9,230)	(3,560)	(4,028)	(2,489)
Equity raised/(repaid)	0	0	0	0	0
Debt raised/(repaid)	(16,609)	(7,473)	(2,226)	(1,182)	(594)
Payment of lease liabilities	0	0	0	0	(1,483)
Interest paid	(4,277)	(2,361)	(2,190)	(1,762)	(1,282)
Dividend paid (incl tax)	(595)	(1,420)	(2,738)	(3,590)	(4,314)
Others	0	0	0	0	0
Financing cash flow	(21,480)	(11,253)	(7,154)	(6,535)	(6,190)
Net chg in Cash	14,724	(2,828)	9,599	14,625	19,777
OCF	3,631	17,655	20,314	25,188	28,456
Adj. OCF (w/o NWC chg.)	5,376	16,983	20,360	24,415	27,759
FCFF	(491)	8,078	14,905	18,596	22,882
FCFE	(9,639)	1,936	7,786	11,481	16,003
OCF/EBITDA (%)	89.7	97.8	92.5	94.8	94.6
FCFE/PAT (%)	343.6	18.4	56.9	64.0	74.2
FCFF/NOPLAT (%)	4,346.7	77.6	117.6	115.4	123.7

Source: Company, Emkay Research

Source: Company, Emkay Research

**Balance Sheet** 

Valuations and key	Ratios				
Y/E Mar	FY22	FY23	FY24E	FY25E	FY26E
P/E (x)	(250.6)	67.0	51.4	39.2	32.6
P/CE(x)	560.1	48.0	38.7	31.0	26.6
P/B (x)	10.0	8.8	7.5	6.3	5.3
EV/Sales (x)	22.9	11.9	10.0	8.6	7.5
EV/EBITDA (x)	172.9	38.3	30.9	25.0	21.4
EV/EBIT(x)	(53,841.0)	49.8	38.9	30.4	25.6
EV/IC (x)	8.5	8.0	7.6	7.3	7.1
FCFF yield (%)	(0.1)	1.2	2.2	2.8	3.5
FCFE yield (%)	(1.4)	0.3	1.1	1.6	2.3
Dividend yield (%)	0.0	0.0	0.0	0.0	0.0
DuPont-RoE split					
Net profit margin (%)	(9.2)	18.1	20.2	23.2	25.0
Total asset turnover (x)	0.4	0.6	0.7	0.7	0.7
Assets/Equity (x)	1.6	1.2	1.1	1.1	1.1
RoE (%)	(5.2)	14.0	15.8	17.6	17.8
DuPont-RoIC					
NOPLAT margin (%)	0.0	17.9	18.7	20.8	21.5
IC turnover (x)	0.4	0.7	0.8	0.9	1.0
RoIC (%)	0.0	12.3	14.4	18.0	20.4
Operating metrics					
Core NWC days	(22.1)	(12.8)	(11.4)	(11.2)	(11.3
Total NWC days	(18.6)	(10.8)	(6.3)	(6.3)	(5.7)
Fixed asset turnover	0.4	0.7	0.8	0.9	0.9
Opex-to-revenue (%)	78.3	60.8	59.8	57.9	57.3

Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions com use and downloaded at 05/01/2024 09:20 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

# **RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
03-Jan-24	451	485	Add	Santosh Sinha
04-Dec-23	434	455	Add	Santosh Sinha
30-Nov-23	422	455	Add	Santosh Sinha
29-Oct-23	375	455	Buy	Santosh Sinha
05-Oct-23	418	485	Buy	Santosh Sinha

Source: Company, Emkay Research

### **RECOMMENDATION HISTORY - TREND**



Source: Company, Bloomberg, Emkay Research

This report is intended for team emkay@whitemarguesolutions.com use and downloaded at 05/01/2024 09:20 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014, EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information. It is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 05/01/2024 09:20 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

#### RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

#### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- EGESL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in 1. the securities recommended in this report as of February 2, 2024
- GFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report 2. Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report З during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities 4. recommended in this report as of February 2, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the 5. subject company at the end of the month immediately preceding the February 2, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months. 6.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for
- investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

### **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

#### Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkavglobal.com

bis report is intended for team emkay @ whitemarguesolutions com use and downloaded at 05/01/2024 09:20 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

#### **OTHER DISCLAIMERS AND DISCLOSURES:**

### Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

his report is intended for team emkay@whitemarguesolutions com use and downloaded at 05/01/2024 09:20 AM Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>.Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futurez Rady Category.